Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clin Cancer Res. 2020 07 15; 26(14):3546-3556.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
Dose-Response Relationship, Drug
Drug Administration Schedule
Drugs, Investigational
Female
fms-Like Tyrosine Kinase 3
Humans
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Protein Kinase Inhibitors
Pyrimidines
Pyrrolidinones
Syk Kinase
Treatment Outcome
Young Adult